Core Viewpoint - Growth investors are attracted to stocks with above-average financial growth, but identifying stocks that can sustain this growth is challenging due to associated risks and volatility [1] Group 1: Company Overview - Insulet (PODD) is highlighted as a recommended growth stock with a favorable Growth Score and a top Zacks Rank [2] - The company specializes in insulin infusion systems, which positions it well in the healthcare sector [3] Group 2: Earnings Growth - Insulet has a historical EPS growth rate of 161.2%, with projected EPS growth of 51% this year, significantly surpassing the industry average of 11.2% [4] Group 3: Cash Flow Growth - The year-over-year cash flow growth for Insulet is 17.4%, exceeding the industry average of 3.5% [5] - Over the past 3-5 years, Insulet's annualized cash flow growth rate has been 51.1%, compared to the industry average of 8.9% [6] Group 4: Earnings Estimate Revisions - The current-year earnings estimates for Insulet have been revised upward, with a 0.1% increase in the Zacks Consensus Estimate over the past month [7] Group 5: Investment Potential - Insulet holds a Zacks Rank of 2 and a Growth Score of A, indicating its potential as an outperformer and a solid choice for growth investors [9]

Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. However, it isn't easy to find a great growth stock.In addition to volatility, these stocks carry above-average risk by their very nature. Also, one could end up losing from a stock whose growth story is actually over or nearing its end.However, the task of finding cutting-edge growth stocks is made easy with the help of the Zacks Growth Sty ...

Core Viewpoint - Investors are increasingly seeking growth stocks that demonstrate above-average growth potential, with Insulet (PODD) being highlighted as a strong candidate due to its favorable growth metrics and Zacks Rank [2][10]. Earnings Growth - Insulet has a historical EPS growth rate of 161.2%, with projected EPS growth of 50.8% for the current year, significantly outperforming the industry average of 12.2% [5][4]. Cash Flow Growth - The company exhibits a year-over-year cash flow growth of 17.4%, which is substantially higher than the industry average of 2.6%. Over the past 3-5 years, Insulet's annualized cash flow growth rate has been 51.1%, compared to the industry average of 8.2% [6][7]. Earnings Estimate Revisions - There has been a positive trend in earnings estimate revisions for Insulet, with the Zacks Consensus Estimate for the current year increasing by 6% over the past month, indicating strong near-term stock price movement potential [8][10]. Overall Positioning - Insulet holds a Zacks Rank of 2 (Buy) and a Growth Score of A, positioning it well for potential outperformance in the growth stock category [10].

Core Viewpoint - Growth stocks are appealing due to their potential for above-average financial growth, but identifying the right ones can be challenging due to associated risks and volatility [1] Earnings Growth - Insulet has a historical EPS growth rate of 147.8%, with projected EPS growth of 43.8% this year, significantly outperforming the industry average of 13.5% [5] Cash Flow Growth - Insulet's year-over-year cash flow growth stands at 17.4%, well above the industry average of 2.5%. The company's annualized cash flow growth rate over the past 3-5 years is 51.1%, compared to the industry average of 8.2% [6][7] Earnings Estimate Revisions - There has been a positive trend in earnings estimate revisions for Insulet, with the Zacks Consensus Estimate for the current year increasing by 0.5% over the past month [9] Overall Positioning - Insulet holds a Zacks Rank of 2 and a Growth Score of A, indicating strong potential for outperformance in the growth stock category [11]

Core Viewpoint - Investors are increasingly seeking growth stocks that demonstrate above-average growth potential, with Insulet (PODD) identified as a strong candidate due to its favorable growth metrics and Zacks Rank [2][8]. Earnings Growth - Insulet has a historical EPS growth rate of 147.8%, with projected EPS growth of 43% this year, significantly outperforming the industry average of 15% [4]. Cash Flow Growth - The company exhibits a year-over-year cash flow growth of 17.4%, compared to an industry average of -0.1%, indicating strong cash generation capabilities [5]. - Over the past 3-5 years, Insulet's annualized cash flow growth rate has been 51.1%, well above the industry average of 8.2% [6]. Earnings Estimate Revisions - There has been a positive trend in earnings estimate revisions for Insulet, with the Zacks Consensus Estimate for the current year increasing by 0.9% over the past month [7]. Overall Assessment - Insulet holds a Zacks Rank of 2 (Buy) and a Growth Score of A, making it a compelling option for growth investors [8][9].